Results 141 to 150 of about 1,571,779 (177)

Acute erythroblastic leukemia. Cytological, cytogenetic and phenotypic studies in one case.

Acta haematologica, 1989
We report the clinical, cytological, immunophenotypic, and cytogenetic findings in one patient with acute erythroblastic leukemia. Blast cells were identified by their reactivity with the early erythroid antibodies FA6-152 and carbonic anhydrase I. The leukemic blasts had no specific differentiating features identifying them as erythroblasts even at an
J, Soler, N, Pujol-Moix, M A, Bosch, C, Guanyabens, A, Aventin, C, Boque, S, Brunet   +6 more
openaire   +1 more source

Acute nonlymphocytic leukemias following chemotherapy. Ultrastructural study of erythroblastic cell line and discussion of nuclear anomalies.

Blood cells, 1982
In 18 cases of drug-induced acute leukemia, electron microscopy brought out a number of anomalies found in all hematopoietic cell lines. They are described here for the erythroblastic line. Some of these anomalies occur in the cytoplasm (like siderosomes, iron-containing mitochondria, glycogen spots, various dense inclusions, and nuclear-cytoplasmic ...
J P, Thiery, A, Aurias, J, Dumont, A, Mazabraud, P, Trapet   +4 more
openaire   +1 more source

Kinetic behavior of 'pathological' myeloblasts and 'normal' erythroblasts in acute granulocytic leukemia. Analysis of in vitro studies in 20 patients.

Oncology, 1983
Kinetic studies of leukemic blast cells (LBC) and erythroblasts were carried out in 20 cases of acute myeloblastic leukemia (AML), and the results were compared with those observed in dividing granulocytic precursors (DGP) and erythroblasts in a control group of 16 normal subjects.
J, Sánchez-Fayos, J, Outeiriño, J M, Fernández-Rañada, M T, Calabuig   +3 more
openaire   +1 more source

PREreview of "Loss of erythroblasts in acute myeloid leukemia causes iron redistribution with clinical implications"

This Zenodo record is a permanently preserved version of a PREreview. You can view the complete PREreview at https://prereview.org/reviews/21282948. Major issues 1. Reliance on a single AML mouse model The study relies almost exclusively on the MLL-AF9 syngeneic AML model. Given the marked biological heterogeneity of AML, validation in additional
openaire   +1 more source

[Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin].

Vnitrni lekarstvi, 2000
Erythroid and/or megakaryocytic dysplasia (EMD) was evaluated in diagnostic bone marrow smears of 37 consecutively treated cases with de novo acute myeloid leukemia (AML) M0-M2 and M4-M5 types and three newly diagnosed cases of refractory anaemia with excess of blasts in transformation.
P, Lemez, J, Gáliková, T, Haas
openaire   +1 more source

First case of bacteremia due to chromosome-encoded CfxA3-beta-lactamase-producing Capnocytophaga sputigena in a pediatric patient with acute erythroblastic leukemia.

European journal of medical research, 2008
Bacteremia due to Capnocytophaga sputigena occurred in a 4-year and 9-month-old Japanese girl patient with acute erythroblastic leukemia in Shinshu University Hospital, Japan. On her admission to the hospital, she had a temperature of 38.2 degrees C with canker sore.
T, Matsumoto, M, Matsubara, K, Oana, E, Kasuga, T, Suzuki, E, Hidaka, T, Shigemura, K, Yamauchi, T, Honda, H, Ota, Yoshiyuki, Kawakami   +10 more
openaire   +1 more source

Do de novo acute myeloid leukemias with normal cytogenetics involve two main prognostic categories distinguished by the presence of erythroblastic and/or megakaryocytic dysplasia?

Neoplasma, 2000
De novo acute myeloid leukemias (AML) patients with normal cytogenetics represent a standard risk cytogenetic group. Erythroblastic and/or megakaryocytic dysplasia (EMD) in diagnostic bone marrow smears of 28 consecutive AML patients with a normal karyotype was studied.
P, Lemez, J, Gáliková, T, Haas
openaire   +1 more source

[Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7].

Vnitrni lekarstvi, 2010
Chemotherapy in most patients with AML over 80 years of age is not recommended because their median survival is about 1 month. The aim of our study was to identify patients in this age group who might achieve complete remission with standard dose chemotherapy. We report 9 consecutive patients with de novo AML diagnosed and treated in 1992-2008.
P, Lemez, J, Gáliková, K, Michalová, D, Dvoráková, A, MacWhannell, Z, Zemanová, J, Stejskal   +6 more
openaire   +1 more source

Isochromosome 11q in acute erythroblastic leukemia

Leukemia Research, 1992
openaire   +2 more sources

CIC‐Rearrangements in Pediatric Acute Erythroid Leukemia/Erythroblastic Sarcoma

Pediatric Blood & Cancer
Alexandra L. Chang‐Graham, Thien Nguyen, Jean Oak, Oscar Silva, Tanja A. Gruber   +4 more
openaire   +2 more sources